BEAT vs. ICCM, SRTS, AMIX, HSAQ, SEPA, CTSO, DXR, NSPR, APYX, and XAIR
Should you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include IceCure Medical (ICCM), Sensus Healthcare (SRTS), Autonomix Medical (AMIX), Health Sciences Acquisitions Co. 2 (HSAQ), SEP Acquisition (SEPA), Cytosorbents (CTSO), Daxor (DXR), InspireMD (NSPR), Apyx Medical (APYX), and Beyond Air (XAIR). These companies are all part of the "surgical & medical instruments" industry.
BioTelemetry (NASDAQ:BEAT) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.
BioTelemetry has a net margin of 0.00% compared to IceCure Medical's net margin of -453.76%. IceCure Medical's return on equity of -86.96% beat BioTelemetry's return on equity.
BioTelemetry received 371 more outperform votes than IceCure Medical when rated by MarketBeat users. However, 94.44% of users gave IceCure Medical an outperform vote while only 63.71% of users gave BioTelemetry an outperform vote.
7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 7.3% of BioTelemetry shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
BioTelemetry has a beta of -1.22, indicating that its stock price is 222% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.
BioTelemetry currently has a consensus price target of $6.78, indicating a potential upside of 210.78%. IceCure Medical has a consensus price target of $2.95, indicating a potential upside of 152.14%. Given BioTelemetry's higher possible upside, equities research analysts clearly believe BioTelemetry is more favorable than IceCure Medical.
BioTelemetry has higher earnings, but lower revenue than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioTelemetry had 1 more articles in the media than IceCure Medical. MarketBeat recorded 2 mentions for BioTelemetry and 1 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 1.00 beat BioTelemetry's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the news media.
Summary
BioTelemetry and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.
Get BioTelemetry News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioTelemetry Competitors List
Related Companies and Tools
